Advertisement

European Journal of Clinical Pharmacology

, Volume 69, Issue 7, pp 1477–1483 | Cite as

Geographical differences in the prevalence of chronic polypharmacy in older people: eleven years of the EPIFARM-Elderly Project

  • Carlotta Franchi
  • Massimo Cartabia
  • Paolo Risso
  • Daniela Mari
  • Mauro Tettamanti
  • Alberto Parabiaghi
  • Luca Pasina
  • Codjo Djignefa Djade
  • Ida Fortino
  • Angela Bortolotti
  • Luca Merlino
  • Alessandro Nobili
Pharmacoepidemiology and Prescription

Abstract

Purpose

To compare the geographical differences in the prevalence of chronic polypharmacy in community-dwelling older people over 11 years.

Methods

This study analyzed nearly two million patients aged 65–94 years recorded in the Drug Administrative Database of the Lombardy Region (Northern Italy) from 2000 to 2010. Chronic polypharmacy was defined as taking five or more drugs in 1 month for at least 6 months (consecutive or not) in a year.

Results

There was a significant spatial autocorrelation that increased at the municipality level from 2000 (Moran’s I Index = 0.26, z score = 16.91, p < 0.0001) to 2010 (Moran’s I Index = 0.36, z score = 23.78, p < 0.0001). Clusters of high (Z(G) > 1.96) and low (Z(G) < −1.96) prevalence rates of chronic polypharmacy were found and were not influenced by age. Chronic polypharmacy weakly correlated with hospital admission (2000: ρ = 0.08, p = 0.0032; 2005: ρ = 0.11, p < 0.0001; 2010: ρ = 0.18, p < 0.0001), but not with mortality.

Conclusions

There were geographical differences in the prevalence of older people with chronic polypharmacy that were only partly explained by health indicators. Targeted activities on prescription practice to ensure that the prescribing of chronic polypharmacy is appropriate are required.

Keywords

Older people Chronic polypharmacy Geographical difference Clusters 

Notes

Conflict of interest

None.

References

  1. 1.
    Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300:2867–2878PubMedCrossRefGoogle Scholar
  2. 2.
    Hovstadius B, Petersson G (2012) Factors leading to excessive polypharmacy. Clin Geriatr Med 28:159–172PubMedCrossRefGoogle Scholar
  3. 3.
    Veehof L, Stewart R, Haaijer-Ruskamp F et al (2000) The development of polypharmacy. A longitudinal study. Fam Pract 17:261–267PubMedCrossRefGoogle Scholar
  4. 4.
    Bjerrum L, Rosholm JU, Hallas J et al (1997) Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol 53:7–11PubMedCrossRefGoogle Scholar
  5. 5.
    Jyrkka J, Enlund H, Lavikainen P et al (2011) Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf 20:514–522PubMedCrossRefGoogle Scholar
  6. 6.
    Haider SI, Johnell K, Weitoft GR, Thorslund M, Fastbom J (2009) The influence of educational level on polypharmacy and inappropriate drug use: a register-based study of more than 600,000 older people. J Am Geriatr Soc 57:62–69PubMedCrossRefGoogle Scholar
  7. 7.
    Johnell K, Fastbom J, Rosen M, Leimanis A (2007) Inappropriate drug use in the elderly: a nationwide register-based study. Ann Pharmacother 41:1243–1248PubMedCrossRefGoogle Scholar
  8. 8.
    Johnell K, Klarin I (2007) The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 30:911–918PubMedCrossRefGoogle Scholar
  9. 9.
    Fincke BG, Snyder K, Cantillon C, Gaehde S, Standring P, Fiore L, Brophy M, Gagnon DR (2005) Three complementary definitions of polypharmacy: methods, application and comparison of findings in a large prescription database. Pharmacoepidemiol Drug Saf 14:121–128PubMedCrossRefGoogle Scholar
  10. 10.
    Hallas J (2005) Drug utilization statistics for individual-level pharmacy dispensing data. Pharmacoepidemiol Drug Saf 14:455–463PubMedCrossRefGoogle Scholar
  11. 11.
    Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius A, de Boer A (2001) Comparison of different methods to estimate prevalence of drug use by using pharmacy records. J Clin Epidemiol 54:1181–1186PubMedCrossRefGoogle Scholar
  12. 12.
    Viktil KK, Blix HS, Moger TA, Reikvam A (2007) Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol 63:187–195PubMedCrossRefGoogle Scholar
  13. 13.
    Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, McLachlan AJ, Cumming RG, Handelsman DJ, Le Couteur DG (2012) Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 65(9):989–995PubMedCrossRefGoogle Scholar
  14. 14.
    Shah BM, Hajjar ER (2012) Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med 28:173–186PubMedCrossRefGoogle Scholar
  15. 15.
    Tamura BK, Bell CL, Inaba M, Masaki KH (2012) Outcomes of polypharmacy in nursing home residents. Clin Geriatr Med 28:217–236PubMedCrossRefGoogle Scholar
  16. 16.
    Patterson SM, Hughes CM, Kerse N, Cardwell C, Bradley M (2012) Interventions to improve appropriate polypharmacy for older people. (Review). Cochrane Database Syst Rev (5)Google Scholar
  17. 17.
    Aronson JK (2004) In defence of polypharmacy. Br J Clin Pharmacol 57(2):119–120PubMedCrossRefGoogle Scholar
  18. 18.
    Barry PJ, Gallagher P, Ryan C, O’Mahony D (2007) START (Screening tool to alert doctors to the right treatment)—an evidence based screening tool to detect prescribing omissions in elderly patients. Age Ageing 36:632–638PubMedCrossRefGoogle Scholar
  19. 19.
    Nobili A, Franchi C, Pasina L, Tettamanti M, Baviera M, Monesi L, Roncaglioni C, Riva E, Lucca U, Bortolotti A, Fortino I, Merlino L (2011) Drug utilization and polypharmacy in an Italian elderly population: the EPIFARM-Elderly Project. Pharmacoepidemiol Drug Saf 20:488–496PubMedCrossRefGoogle Scholar
  20. 20.
    Hovstadius B, Astrand B, Petersson G (2010) Assessment of regional variation in polypharmacy. Pharmacoepidemiol Drug Saf 19:375–383PubMedGoogle Scholar
  21. 21.
    Franchi C, Sequi M, Bonati M, Nobili A, Pasina L, Bortolotti A, Fortino I, Merlino L, Clavenna A (2011) Differences in outpatient antibiotic prescription in Italy’s Lombardy region. Infection 39:299–308PubMedCrossRefGoogle Scholar
  22. 22.
    Franchi C, Tettamanti M, Marengoni A, Bonometti F, Pasina L, Cortesi L, Fortino I, Bortolotti A, Merlino L, Lucca U, Riva E, Nobili A (2012) Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project. Eur Neuropsychopharmacol 22(8):569–577PubMedCrossRefGoogle Scholar
  23. 23.
    WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical (ATC) classification. About the ATC/DDD system. http://www.whocc.no/atcddd/. Accessed 15 June 2012
  24. 24.
    Istituto Nazionale di Statistica (ISTAT). http://www.istat.it/it/archivio/44523. Accessed 15 July 2012
  25. 25.
    Getis A, Ord JK (1992) The analysis of spatial association by use of distance statistics. Geogr Anal 24:3Google Scholar
  26. 26.
    Anderson GF (2005) Medicare and chronic conditions. N Engl J Med 353:305–309PubMedCrossRefGoogle Scholar
  27. 27.
    Milton JC, Hill-Smith I, Jackson SHD (2008) Prescribing for older people. BMJ 336:606–609PubMedCrossRefGoogle Scholar
  28. 28.
    Omar RZ, O’Sullivan C, Petersen I, Islam A, Majeed A (2008) A model based on age, sex, and morbidity to explain variation in UK general practice prescribing: cohort study. Br Med J 337:238CrossRefGoogle Scholar
  29. 29.
    Grimmsmann T, Himmel W (2009) Polypharmacy in primary care practices: an analysis using a large health insurance database. Pharmacoepidemiol Drug Saf 18:1206–1213PubMedCrossRefGoogle Scholar
  30. 30.
    Bjerrum L, Søgaard J, Hallas J, Kragstrup J (1999) Polypharmacy in general practice: differences between practitioners. Br J Gen Pract 49(440):195–198PubMedGoogle Scholar
  31. 31.
    Progetto ARNO: Rapporto sul profilo prescrittivo della popolazione anziana. Rapporto 2001. CINECA. Centauro Editore, Bologna 2002Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Carlotta Franchi
    • 1
  • Massimo Cartabia
    • 2
  • Paolo Risso
    • 3
  • Daniela Mari
    • 4
  • Mauro Tettamanti
    • 5
  • Alberto Parabiaghi
    • 3
  • Luca Pasina
    • 1
  • Codjo Djignefa Djade
    • 1
  • Ida Fortino
    • 6
  • Angela Bortolotti
    • 6
  • Luca Merlino
    • 6
  • Alessandro Nobili
    • 1
  1. 1.Laboratory for Quality Assessment of Geriatric Therapies and ServicesIstituto di Ricerche Farmacologiche Mario Negri-IRCCSMilanItaly
  2. 2.Laboratory of Mother and Child HealthIstituto di Ricerche Farmacologiche Mario Negri-IRCCSMilanItaly
  3. 3.Laboratory of Epidemiology and Social PsychiatryIstituto di Ricerche Farmacologiche Mario Negri-IRCCSMilanItaly
  4. 4.IRCCS Maggiore Hospital Foundation and University of Milan, Department of Clinical Sciences and Community Health, Geriatric UnitMilanItaly
  5. 5.Laboratory of Geriatric NeuropsychiatryIstituto di Ricerche Farmacologiche Mario Negri-IRCCSMilanItaly
  6. 6.Regional Health Ministry, Lombardy RegionMilanItaly

Personalised recommendations